Allmed Solutions

Allmed Solutions FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Allmed Solutions (ALMD.TA) as of Nov 5, 2026 is 85.85 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 93,041.59 % — a change of -99.91% (lower).

FCF Conversion

85.85 %

YoY

-99.91%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Allmed Solutions is 2025 85.85 % . FCF Conversion Rate (FCF/EBITDA) of Allmed Solutions was 2024 93,041.59 % . It decreases by -99.91% lower compared to the previous year.

The Allmed Solutions FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
80.45 ILS
Jan 1, 2019
-56.44 ILS
Jan 1, 2020
103.34 ILS
Jan 1, 2021
-196.62 ILS
Jan 1, 2022
95,175.56 ILS
Jan 1, 2023
493,459.92 ILS
Jan 1, 2024
93,041.59 ILS
Jan 1, 2025
85.85 ILS
The Allmed Solutions FCF Conversion history
YEARFCF ConversionYoY
85.85 %-99.91%
93,041.59 %-81.15%
493,459.92 %+418.47%
95,175.56 %-48,506.62%
-196.62 %-290.27%
103.34 %-283.11%
-56.44 %-170.15%
80.45 %-3.55%
83.42 %+14.06%
73.13 %-4.55%
76.62 %-2.74%
78.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Allmed Solutions Stock analysis

What does Allmed Solutions do? Allmed Solutions Ltd, based in Caesarea, Israel, is listed on the stock market since 2007. The company develops, manufactures, and markets minimally invasive medical products globally. Its product portfolio includes Covered Stents for urinary and biliary conditions, Uro-Gynecology solutions for pelvic organ prolapse and incontinence, Type II Diabetes treatments like the Gastro-duodenal sleeve, and Cardiovascular devices such as the WIRION EPD System. These products address medical needs including pelvic organ prolapse, urinary incontinence, and carotid stenosis worldwide. Allmed Solutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Allmed Solutions stock

FCF Conversion Rate (FCF/EBITDA) of Allmed Solutions is 85.85 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Allmed Solutions changed from 93,041.59 % to 85.85 %, representing a -99.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Allmed Solutions since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Allmed Solutions with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Allmed Solutions

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Allmed Solutions